Pages that link to "Q37911387"

The following pages link to The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms (Q37911387):

Displaying 43 items.

• Role of cytochrome P450 in drug interactions (Q21245066) (← links)
• Crystal structure of human cytochrome P450 2D6 (Q24298673) (← links)
• Application of genomics to toxicology research (Q24812775) (← links)
• Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system (Q33630990) (← links)
• Clinically significant pharmacokinetic drug interactions between antiepileptic drugs (Q33668831) (← links)
• Gender-related differences in pharmacokinetics and their clinical significance (Q33785861) (← links)
• Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping (Q33921325) (← links)
• Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. (Q34152279) (← links)
• LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase (Q34205552) (← links)
• The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. (Q34400605) (← links)
• Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone (Q34403471) (← links)
• Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population (Q34403562) (← links)
• Metabolic activation of toxins: tissue-specific expression and metabolism in target organs (Q34638922) (← links)
• Multiple genetic alterations in human carcinogenesis (Q34843882) (← links)
• Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications (Q35024501) (← links)
• The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. (Q35828032) (← links)
• Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. (Q36761673) (← links)
• Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we? (Q38017920) (← links)
• Consequences of daily corticosteroid dosing with or without pre-treatment with quinidine on the in vivo cytochrome P450 2D (CYP2D) enzyme in rats: effect on O-demethylation activity of dextromethorphan and expression levels of CYP2D1 mRNA. (Q39068391) (← links)
• Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review (Q40442625) (← links)
• In vitro methods for assessing human hepatic drug metabolism: their use in drug development (Q40817420) (← links)
• Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism (Q40931793) (← links)
• Thalidomide-induced neuropathy and genetic differences in drug metabolism (Q42554772) (← links)
• 20 Immunoisolation of human microsomal cytochromes P450 using autoantibodies (Q44491662) (← links)
• Endogenous and exogenous factors modifying the activity of human liver cytochrome P-450 enzymes (Q44576033) (← links)
• Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis (Q45250502) (← links)
• Strain differences in age-associated change in testosterone 6β-hydroxylation in Wistar and Dark Agouti rats (Q47754740) (← links)
• Regional and cellular distribution of CYP2D subfamily members in rat brain (Q51975320) (← links)
• Combined genetic polymorphism and risk for development of lung cancer (Q53438264) (← links)
• DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers (Q61591076) (← links)
• Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers (Q67593712) (← links)
• Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? (Q67826302) (← links)
• Metabolism of debrisoquine and susceptibility to breast cancer (Q67919493) (← links)
• 49 Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6 (Q68332109) (← links)
• Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of ( /-)-metoprolol (Q70493631) (← links)
• Measurement of human liver microsomal cytochrome P450 2D6 activity using [O-methyl-14C]dextromethorphan as substrate (Q71497755) (← links)
• Strain differences in adrenal CYP2D16 expression in guinea pigs. Relationship to xenobiotic metabolism (Q71850715) (← links)
• Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine (Q72345196) (← links)
• A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building (Q72933430) (← links)
• Extension of a predictive substrate model for human cytochrome P4502D6 (Q73335838) (← links)
• Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia (Q73417857) (← links)
• Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes (Q73846452) (← links)
• An improved HPLC method for analysis of methamphetamine and its metabolites in plasma (Q74346178) (← links)